{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-280159","form_type":"8-K","ticker":"INO","cik":"0001055726","company_name":"INOVIO PHARMACEUTICALS, INC.","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.440700+00:00","generated_at":"2026-06-22T02:43:57.431513+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"INOVIO Q3 net loss narrows to $0.15/sh; cash runway into Q1 2025","bullets":["Q3 2022 revenue of $9.2M vs $292K in Q3 2021, driven by DoD contract.","Net loss $37.8M ($0.15/sh) vs $60.2M ($0.29/sh) prior year; OpEx down to $44.9M.","Cash and investments $281.9M; guidance extended to early 2025 with ~$45M Q4 cash burn.","Discontinued internal INO-4800 heterologous COVID-19 booster; redeploying savings to other programs.","Positive interim INO-3107 data: median 3 fewer RRP surgeries; 29% needed no intervention in 52 weeks."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-280159","json":"https://secwatch.observer/filing/0001193125-22-280159.json","markdown":"https://secwatch.observer/filing/0001193125-22-280159.md","text":"https://secwatch.observer/filing/0001193125-22-280159.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1055726/000119312522280159/0001193125-22-280159-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1055726/000119312522280159/d280542d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T02:43:57.431513+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5cddec6e812654784e17b5d0b8f1fc8681837cee","claim":"INOVIO PHARMACEUTICALS, INC. reported third quarter and nine months ended September 30, 2022 results: revenue $9.2 million, net income $37.8 million, or $0.15 per basic and diluted share, EPS $0.15 per basic and diluted share.","evidence_excerpt":"vesting, and conversion, as applicable, of its outstanding options, restricted stock units, convertible preferred stock, and convertible debt. INOVIO reported total revenue of $9.2 million for the three months ended, September 30, 2022, compared to $292,000 for the same period in 2021. The increase in revenue resulted from the fulfillment of obligations under its","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1055726/000119312522280159/0001193125-22-280159-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter and nine months ended September 30, 2022"},{"label":"Revenue","value":"$9.2 million"},{"label":"Net income","value":"$37.8 million, or $0.15 per basic and diluted share"},{"label":"EPS","value":"$0.15 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}